CL2013001345A1 - Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano-4-sustituidos, antagonistas del receptor mglur 2/3; composicion farmaceutica que comprende uno de estos compuestos; y composicion farmaceutica que comprende uno de estos compuestos y un inhibidor de la reabsorcion de serotonina, tal como fluoxetina o citalopram. - Google Patents

Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano-4-sustituidos, antagonistas del receptor mglur 2/3; composicion farmaceutica que comprende uno de estos compuestos; y composicion farmaceutica que comprende uno de estos compuestos y un inhibidor de la reabsorcion de serotonina, tal como fluoxetina o citalopram.

Info

Publication number: CL2013001345A1
Authority: CL; Chile
Prior art keywords: compounds; pharmaceutical composition; phenylsulfanylmethyl; citalopram; fluoxetine
Prior art date: 2010-11-18

Application number

CL2013001345A

Other languages

English (en)

Inventor

Stephon Cornell Smith

Renhua Ll

Charles Howard Mitch

Tatiana Natali Vetman

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-18

Filing date

2013-05-15

Publication date

2013-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45099188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001345(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-15 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2013-11-15 Publication of CL2013001345A1 publication Critical patent/CL2013001345A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2013001345A 2010-11-18 2013-05-15 Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano-4-sustituidos, antagonistas del receptor mglur 2/3; composicion farmaceutica que comprende uno de estos compuestos; y composicion farmaceutica que comprende uno de estos compuestos y un inhibidor de la reabsorcion de serotonina, tal como fluoxetina o citalopram. CL2013001345A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41512110P	2010-11-18	2010-11-18

Publications (1)

Publication Number	Publication Date
CL2013001345A1 true CL2013001345A1 (es)	2013-11-15

Family

ID=45099188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001345A CL2013001345A1 (es)	2010-11-18	2013-05-15	Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano-4-sustituidos, antagonistas del receptor mglur 2/3; composicion farmaceutica que comprende uno de estos compuestos; y composicion farmaceutica que comprende uno de estos compuestos y un inhibidor de la reabsorcion de serotonina, tal como fluoxetina o citalopram.

Country Status (37)

Country	Link
US (1)	US8629169B2 (es)
EP (1)	EP2640697B1 (es)
JP (1)	JP5877847B2 (es)
KR (2)	KR20130101094A (es)
CN (1)	CN103228625B (es)
AR (1)	AR083845A1 (es)
AU (1)	AU2011329076B2 (es)
BR (1)	BR112013012118A2 (es)
CA (1)	CA2818116C (es)
CL (1)	CL2013001345A1 (es)
CO (1)	CO6761385A2 (es)
CR (1)	CR20130178A (es)
DK (1)	DK2640697T3 (es)
DO (1)	DOP2013000099A (es)
EA (1)	EA021724B1 (es)
EC (1)	ECSP13012629A (es)
ES (1)	ES2650139T3 (es)
GT (1)	GT201300126A (es)
HR (1)	HRP20171649T1 (es)
HU (1)	HUE037457T2 (es)
IL (1)	IL225843A (es)
LT (1)	LT2640697T (es)
MA (1)	MA34663B1 (es)
MX (1)	MX339973B (es)
NO (1)	NO2640697T3 (es)
NZ (1)	NZ609816A (es)
PE (1)	PE20140997A1 (es)
PH (1)	PH12013500991A1 (es)
PL (1)	PL2640697T3 (es)
PT (1)	PT2640697T (es)
RS (1)	RS56535B1 (es)
SG (1)	SG189959A1 (es)
SI (1)	SI2640697T1 (es)
TW (1)	TWI520935B (es)
UA (1)	UA110039C2 (es)
WO (1)	WO2012068067A1 (es)
ZA (1)	ZA201302918B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO2978B1 (en) *	2009-12-21	2016-03-15	ايلي ليلي اند كومباني	MGLU2 aids
EP3000814A1 (en)	2014-09-26	2016-03-30	Domain Therapeutics	Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
PT3445743T (pt)	2016-04-18	2021-08-24	Taisho Pharmaceutical Co Ltd	Pró-fármaco de derivado de aminoácido
US11173145B2 (en)	2017-01-17	2021-11-16	Board Of Regents, The University Of Texas System	Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020018670A1 (en) *	2018-07-17	2020-01-23	Board Of Regents, The University Of Texas System	Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0669928B2 (ja)	1987-10-06	1994-09-07	宇部興産株式会社	光重合性歯科材料
JP2589812B2 (ja)	1989-07-05	1997-03-12	松下電器産業株式会社	スチームアイロン
ZA969485B (en)	1995-11-16	1998-05-12	Lilly Co Eli	Excitatory amino acid receptor antagonists.
EA000894B1 (ru)	1995-11-16	2000-06-26	Эли Лилли Энд Компани	Замещенные бициклогексанкарбоновые кислоты и их производные в качестве антагонистов рецептора возбуждающих аминокислот, способ их получения и применение
ZA983930B (en) *	1997-05-14	1999-11-08	Lilly Co Eli	Excitatory amino acid receptor modulators.
HUP0101031A3 (en) *	1998-03-17	2003-05-28	Pfizer Prod Inc	Bicyclo[2.2.1]heptanes and related compounds
GB9815542D0 (en)	1998-07-17	1998-09-16	Lilly Co Eli	Bicyclohexane derivatives
CH694053A5 (de)	1998-09-03	2004-06-30	Hoffmann La Roche	Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
WO2002068380A1 (en) *	2001-02-22	2002-09-06	Eli Lilly And Company	Synthetic excitatory amino acids
EP1459765B1 (en)	2001-12-27	2008-08-20	Taisho Pharmaceutical Co., Ltd	6-fluorobicyclo 3.1.0 hexane derivatives
MXPA04012518A (es) *	2002-06-11	2005-02-17	Lilly Co Eli	Profarmacos de aminoacidos excitadores.
JP4984529B2 (ja) *	2003-06-26	2012-07-25	大正製薬株式会社	２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体
EP2287147B1 (en)	2003-06-26	2013-05-15	Taisho Pharmaceutical Co., Ltd.	2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
JP2007063129A (ja)	2003-06-26	2007-03-15	Taisho Pharmaceut Co Ltd	２−アミノ−３−アルコキシビシクロ［３．１．０］ヘキサン誘導体
JO2978B1 (en) *	2009-12-21	2016-03-15	ايلي ليلي اند كومباني	MGLU2 aids

2011
- 2011-11-11 AR ARP110104219A patent/AR083845A1/es unknown
- 2011-11-11 TW TW100141326A patent/TWI520935B/zh not_active IP Right Cessation
- 2011-11-15 EA EA201390498A patent/EA021724B1/ru not_active IP Right Cessation
- 2011-11-15 MX MX2013005622A patent/MX339973B/es active IP Right Grant
- 2011-11-15 BR BR112013012118A patent/BR112013012118A2/pt not_active IP Right Cessation
- 2011-11-15 DK DK11791692.4T patent/DK2640697T3/en active
- 2011-11-15 HR HRP20171649TT patent/HRP20171649T1/hr unknown
- 2011-11-15 WO PCT/US2011/060730 patent/WO2012068067A1/en active Application Filing
- 2011-11-15 KR KR1020137012697A patent/KR20130101094A/ko not_active Abandoned
- 2011-11-15 NO NO11791692A patent/NO2640697T3/no unknown
- 2011-11-15 UA UAA201305835A patent/UA110039C2/ru unknown
- 2011-11-15 CN CN201180055263.7A patent/CN103228625B/zh active Active
- 2011-11-15 US US13/296,384 patent/US8629169B2/en active Active
- 2011-11-15 HU HUE11791692A patent/HUE037457T2/hu unknown
- 2011-11-15 RS RS20171082A patent/RS56535B1/sr unknown
- 2011-11-15 JP JP2013539938A patent/JP5877847B2/ja active Active
- 2011-11-15 EP EP11791692.4A patent/EP2640697B1/en active Active
- 2011-11-15 PT PT117916924T patent/PT2640697T/pt unknown
- 2011-11-15 PH PH1/2013/500991A patent/PH12013500991A1/en unknown
- 2011-11-15 ES ES11791692.4T patent/ES2650139T3/es active Active
- 2011-11-15 CA CA2818116A patent/CA2818116C/en active Active
- 2011-11-15 PL PL11791692T patent/PL2640697T3/pl unknown
- 2011-11-15 NZ NZ609816A patent/NZ609816A/en not_active IP Right Cessation
- 2011-11-15 LT LTEP11791692.4T patent/LT2640697T/lt unknown
- 2011-11-15 KR KR1020157034547A patent/KR20150140876A/ko not_active Ceased
- 2011-11-15 AU AU2011329076A patent/AU2011329076B2/en not_active Ceased
- 2011-11-15 SG SG2013030507A patent/SG189959A1/en unknown
- 2011-11-15 PE PE2013001215A patent/PE20140997A1/es not_active Application Discontinuation
- 2011-11-15 SI SI201131304T patent/SI2640697T1/sl unknown
2013
- 2013-04-18 IL IL225843A patent/IL225843A/en not_active IP Right Cessation
- 2013-04-22 ZA ZA2013/02918A patent/ZA201302918B/en unknown
- 2013-04-24 CR CR20130178A patent/CR20130178A/es unknown
- 2013-05-08 DO DO2013000099A patent/DOP2013000099A/es unknown
- 2013-05-13 MA MA35898A patent/MA34663B1/fr unknown
- 2013-05-15 CL CL2013001345A patent/CL2013001345A1/es unknown
- 2013-05-15 GT GT201300126A patent/GT201300126A/es unknown
- 2013-05-17 EC ECSP13012629 patent/ECSP13012629A/es unknown
- 2013-05-30 CO CO13133036A patent/CO6761385A2/es unknown

Also Published As

Publication number	Publication date
GT201300126A (es)	2014-02-27
LT2640697T (lt)	2018-01-10
JP2014505664A (ja)	2014-03-06
EP2640697A1 (en)	2013-09-25
UA110039C2 (xx)	2015-11-10
PE20140997A1 (es)	2014-08-25
KR20130101094A (ko)	2013-09-12
CA2818116C (en)	2016-04-05
MX2013005622A (es)	2013-07-05
NZ609816A (en)	2014-12-24
CN103228625A (zh)	2013-07-31
AU2011329076A1 (en)	2013-05-02
CO6761385A2 (es)	2013-09-30
RS56535B1 (sr)	2018-02-28
BR112013012118A2 (pt)	2016-09-27
EP2640697B1 (en)	2017-09-20
HUE037457T2 (hu)	2018-08-28
CR20130178A (es)	2013-07-09
SI2640697T1 (sl)	2017-11-30
AR083845A1 (es)	2013-03-27
MX339973B (es)	2016-06-20
MA34663B1 (fr)	2013-11-02
TW201307271A (zh)	2013-02-16
IL225843A0 (en)	2013-06-27
KR20150140876A (ko)	2015-12-16
ECSP13012629A (es)	2013-07-31
PH12013500991A1 (en)	2015-02-11
IL225843A (en)	2015-05-31
AU2011329076B2 (en)	2015-03-12
EA021724B1 (ru)	2015-08-31
SG189959A1 (en)	2013-06-28
DK2640697T3 (en)	2017-10-23
WO2012068067A1 (en)	2012-05-24
ZA201302918B (en)	2014-10-29
NO2640697T3 (es)	2018-02-17
TWI520935B (zh)	2016-02-11
EA201390498A1 (ru)	2013-07-30
CN103228625B (zh)	2014-12-03
CA2818116A1 (en)	2012-05-24
DOP2013000099A (es)	2013-08-15
US20120129902A1 (en)	2012-05-24
US8629169B2 (en)	2014-01-14
HRP20171649T1 (hr)	2017-12-15
JP5877847B2 (ja)	2016-03-08
PL2640697T3 (pl)	2018-02-28
ES2650139T3 (es)	2018-01-17
PT2640697T (pt)	2017-12-11

Publication	Publication Date	Title
SMT201600216B (it)	2016-08-31	Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina
DK4374878T3 (da)	2025-05-05	Farmaceutisk sammensætning, der omfatter carbetocin
FR2962608B1 (fr)	2012-08-10	Nouvelles structures de redondance pour convertisseurs statiques
FR2962442B1 (fr)	2016-02-26	Composition stable de 2,3,3,3-tetrafluoropropene
BRPI1012892A2 (pt)	2018-03-13	composto, e, composição farmacêutica.
DK3360538T3 (da)	2023-03-06	Injicerbar, flydende sammensætning omfattende buprenorphin
BR112013003536A2 (pt)	2016-06-28	composição, e utilização de uma composição.
EP2646006A4 (en)	2014-06-25	ARZNEIMITTELDARREICHUNGSFORM
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BR112013001571A2 (pt)	2016-05-10	composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
PL2431442T3 (pl)	2018-09-28	Kompozycja na bazie 1,3,3,3-tetrafluoropropenu
CL2013000733A1 (es)	2013-08-23	Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.
MY173521A (en)	2020-01-30	Trpv4 antagonists
BRPI1010617A2 (pt)	2016-03-15	uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
DK2488145T3 (da)	2024-07-22	Beholdere til sammensætninger omfattende meloxicam
BRPI1011460A2 (pt)	2015-08-25	Composição desinfetante.
DK2493312T3 (da)	2021-12-13	Farmaceutiske faststofsammensætninger, der indeholder en integrase- hæmmer
CL2013001345A1 (es)	2013-11-15	Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano-4-sustituidos, antagonistas del receptor mglur 2/3; composicion farmaceutica que comprende uno de estos compuestos; y composicion farmaceutica que comprende uno de estos compuestos y un inhibidor de la reabsorcion de serotonina, tal como fluoxetina o citalopram.
JP2012523555A5 (es)	2014-01-23
CL2008000430A1 (es)	2008-08-18	Compuestos derivados de heterociclos condensados sustituidos; composicion farmaceutica que comprende a dichos compuestos, utiles para el tratamiento de una o mas condiciones asociadas con receptores adrenergicos a2c, tales como congestion asociada a
CL2013001315A1 (es)	2013-08-02	Composicion que comprende micro-organismo probioticos no replicantes extruidos.
BRPI1010073A2 (pt)	2016-03-15	composição anticancerígina injetável para administração local contendo hidroxicloquina
CL2013002903A1 (es)	2014-05-02	Composicion que comprende azadiractina; metodo para el tratamiento anti-macroincrustacion de al menos un polimeros; y su uso.
ITTO20110268A1 (it)	2011-09-30	Composizione di maquillage.
FR2958159B1 (fr)	2014-06-13	Compostion cosmetique ou pharmaceutique